BACKGROUND: Cryptococcus is a leading cause of AIDS-related mortality. Cryptococcal antigen (CrAg) is detectable in blood before meningitis onset and predicts death. CrAg screening among those with advanced HIV, and treatment of those CrAg+ with fluconazole, has demonstrated survival benefit. However, implementation and widespread uptake have been slow outside clinical trials. METHODS: We designed a CrAg screening program for routine care that incorporated intensive education and training of clinic staff. We evaluated programmatic implementation, including time to initiation of fluconazole, time to initiation of antiretroviral therapy, and 6-month clinical outcomes. RESULTS: Between December 2015 and January 2017, 1440 persons were screened at 11 HIV clinics in Kampala, and CRAG+ prevalence was 6.5% (n = 94/1440) among adults with a CD4 <100 cells/µL. Of those CrAg+, 7 of 94 persons (7%) died or were lost before further clinic evaluation. Fifty-three persons (56%) were asymptomatic and had 6-month survival of 87% (46/53). Of CrAg+ persons, 28% (26/94) were symptomatic at the time of clinic return. Most had confirmed cryptococcal meningitis, and 54% (14/26) of the symptomatic CrAg+ persons were dead or lost at 6 months. Of the 7 symptomatic persons who declined lumbar puncture for further evaluation, all were dead or lost by 6 months. CONCLUSION: All asymptomatic CrAg+ persons identified by our screening program who returned to clinic, initated fluconazole and antiretroviral therapy in a timely manner. Despite this, 27% of CrAg+ (asymptomatic and symptomatic) identified on routine screening were dead or lost to follow-up at 6 months, even with preemptive therapy for those asymptomatic, and standard amphotericin-based treatment for meningitis.
BACKGROUND:Cryptococcus is a leading cause of AIDS-related mortality. Cryptococcal antigen (CrAg) is detectable in blood before meningitis onset and predicts death. CrAg screening among those with advanced HIV, and treatment of those CrAg+ with fluconazole, has demonstrated survival benefit. However, implementation and widespread uptake have been slow outside clinical trials. METHODS: We designed a CrAg screening program for routine care that incorporated intensive education and training of clinic staff. We evaluated programmatic implementation, including time to initiation of fluconazole, time to initiation of antiretroviral therapy, and 6-month clinical outcomes. RESULTS: Between December 2015 and January 2017, 1440 persons were screened at 11 HIV clinics in Kampala, and CRAG+ prevalence was 6.5% (n = 94/1440) among adults with a CD4 <100 cells/µL. Of those CrAg+, 7 of 94 persons (7%) died or were lost before further clinic evaluation. Fifty-three persons (56%) were asymptomatic and had 6-month survival of 87% (46/53). Of CrAg+persons, 28% (26/94) were symptomatic at the time of clinic return. Most had confirmed cryptococcal meningitis, and 54% (14/26) of the symptomatic CrAg+persons were dead or lost at 6 months. Of the 7 symptomatic persons who declined lumbar puncture for further evaluation, all were dead or lost by 6 months. CONCLUSION: All asymptomatic CrAg+persons identified by our screening program who returned to clinic, initated fluconazole and antiretroviral therapy in a timely manner. Despite this, 27% of CrAg+ (asymptomatic and symptomatic) identified on routine screening were dead or lost to follow-up at 6 months, even with preemptive therapy for those asymptomatic, and standard amphotericin-based treatment for meningitis.
Authors: David B Meya; Yukari C Manabe; Barbara Castelnuovo; Bethany A Cook; Ali M Elbireer; Andrew Kambugu; Moses R Kamya; Paul R Bohjanen; David R Boulware Journal: Clin Infect Dis Date: 2010-08-15 Impact factor: 9.079
Authors: Radha Rajasingham; Rachel M Smith; Benjamin J Park; Joseph N Jarvis; Nelesh P Govender; Tom M Chiller; David W Denning; Angela Loyse; David R Boulware Journal: Lancet Infect Dis Date: 2017-05-05 Impact factor: 25.071
Authors: Sayoki Mfinanga; Duncan Chanda; Sokoine L Kivuyo; Lorna Guinness; Christian Bottomley; Victoria Simms; Carol Chijoka; Ayubu Masasi; Godfather Kimaro; Bernard Ngowi; Amos Kahwa; Peter Mwaba; Thomas S Harrison; Saidi Egwaga; Shabbar Jaffar Journal: Lancet Date: 2015-03-10 Impact factor: 79.321
Authors: A-C L Meyer; C K Kendi; J A Penner; N Odhiambo; B Otieno; E Omondi; E Opiyo; E A Bukusi; C R Cohen Journal: Trop Med Int Health Date: 2013-02-01 Impact factor: 2.622
Authors: Joseph N Jarvis; Tihana Bicanic; Angela Loyse; Daniel Namarika; Arthur Jackson; Jesse C Nussbaum; Nicky Longley; Conrad Muzoora; Jacob Phulusa; Kabanda Taseera; Creto Kanyembe; Douglas Wilson; Mina C Hosseinipour; Annemarie E Brouwer; Direk Limmathurotsakul; Nicholas White; Charles van der Horst; Robin Wood; Graeme Meintjes; John Bradley; Shabbar Jaffar; Thomas Harrison Journal: Clin Infect Dis Date: 2013-12-06 Impact factor: 9.079
Authors: Emilio Letang; Matthias C Müller; Alex J Ntamatungiro; Namvua Kimera; Diana Faini; Hansjakob Furrer; Manuel Battegay; Marcel Tanner; Christoph Hatz; David R Boulware; Tracy R Glass Journal: Open Forum Infect Dis Date: 2015-04-02 Impact factor: 3.835
Authors: Diksha Srishyla; Gabriel Saemisch; Fred Turya; Elizabeth Nalintya; Samuel Jjunju; Enock Kagimu; Morris K Rutakingirwa; Caleb P Skipper; David R Boulware; David B Meya; Radha Rajasingham Journal: Med Mycol Date: 2022-04-01 Impact factor: 4.076
Authors: Kenneth Ssebambulidde; Ananta S Bangdiwala; Richard Kwizera; Tadeo Kiiza Kandole; Lillian Tugume; Reuben Kiggundu; Edward Mpoza; Edwin Nuwagira; Darlisha A Williams; Sarah M Lofgren; Mahsa Abassi; Abdu K Musubire; Fiona V Cresswell; Joshua Rhein; Conrad Muzoora; Kathy Huppler Hullsiek; David R Boulware; David B Meya Journal: Clin Infect Dis Date: 2019-05-30 Impact factor: 9.079
Authors: David R Boulware; Elizabeth Nalintya; Radha Rajasingham; Paul Kirumira; Rose Naluyima; Fred Turya; Sylvia Namanda; Morris K Rutakingirwa; Caleb P Skipper; Yofesi Nikweri; Kathy Huppler Hullsiek; Ananta S Bangdiwala; David B Meya Journal: Med Mycol Date: 2020-11-10 Impact factor: 4.076
Authors: Radha Rajasingham; David B Meya; Gregory S Greene; Alexander Jordan; Mina Nakawuka; Tom M Chiller; David R Boulware; Bruce A Larson Journal: PLoS One Date: 2019-01-10 Impact factor: 3.240
Authors: Sarah M Lofgren; Elizabeth Nalintya; David B Meya; David R Boulware; Radha Rajasingham Journal: Medicine (Baltimore) Date: 2018-08 Impact factor: 1.817
Authors: Elliot S Gerlach; Sophie Altamirano; J Marina Yoder; Tony S Luggya; Andrew Akampurira; David B Meya; David R Boulware; Joshua Rhein; Kirsten Nielsen Journal: Front Cell Infect Microbiol Date: 2021-06-23 Impact factor: 5.293